Shares of Inovio Pharmaceuticals Inc. rose 9% in premarket trade Thursday after the company announced that its investigational Ebola vaccine was able to elicit a strong antibody response in the majority of subjects in a Phase 1 trial. The vaccine, dubbed INO-4201, was given to 70 subjects either through a skin injection or an injection into muscle. Of those subjects, 67 were able to mount a strong antibody response to an Ebola antigen after three doses, while 52 were able to do so after only two doses, the company said. Inovio noted that the 13 subjects who received the vaccine through a skin injection were all able to mount an antigen-specific antibody response after just two doses. The vaccine, which is non-live as opposed to other investigational Ebola vaccines based on viral vectors, has not shown any serious systemic adverse effects like fever, joint pain or low white blood cell count, the company said. Shares of Inovio have fallen 10% in the year to date, while the S&P 500 has gained 12.7%.